IMMUNE CHECKPOINTS AS KEY BIOMARKERS OF ANTITUMOR THERAPY EFFECTIVENESS IN BREAST CANCER

Abstract

The study examines immune checkpoint molecules PD-1 and PD-L1 as key biomarkers of antitumor therapy efficacy in breast cancer. Expression levels of PD-1/PD-L1, cytokine profiles (IL-2, IL-6, IL-10, TNF-α, IFN-γ), and immune cell subpopulations were analyzed in 290 patients with various molecular subtypes. Significant correlations were found between PD-L1 expression, tumor aggressiveness, and treatment response. Integrated clinical-immunological indices were developed to predict therapeutic effectiveness and recurrence risk. The findings highlight the prognostic and predictive significance of immune checkpoints in personalizing treatment strategies and improving therapeutic outcomes in breast cancer